Stockscreener 앱 받기
6.18
3.34%
0.20
시간 외 거래:
6.18
전일 마감가:
$5.98
열려 있는:
$6.05
하루 거래량:
650.24K
Relative Volume:
0.79
시가총액:
$406.98M
수익:
$301.79M
순이익/손실:
$-43.42M
주가수익비율:
-9.217
EPS:
-0.6705
순현금흐름:
$-44.87M
1주 성능:
+11.45%
1개월 성능:
-13.32%
6개월 성능:
+24.85%
1년 성능:
-35.15%
1일 변동 폭
$6.05
$6.31
1주일 범위
$5.47
$6.31
52주 변동 폭
$3.86
$9.58
Evolus Inc Stock (EOLS) Company Profile
명칭
Evolus Inc
전화
(949) 284-4555
주소
520 NEWPORT CENTER DRIVE, NEWPORT BEACH
Compare EOLS vs TAK, HLN, TEVA, ZTS, UTHR
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
EOLS
Evolus Inc
|
6.18 | 393.81M | 301.79M | -43.42M | -44.87M | -0.6705 |
TAK
Takeda Pharmaceutical Co Adr
|
17.44 | 55.06B | 29.91B | 1.30B | 3.49B | 0.4056 |
HLN
Haleon Plc Adr
|
9.94 | 43.07B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
31.08 | 35.88B | 17.53B | 1.58B | 444.18M | 1.3457 |
ZTS
Zoetis Inc
|
76.92 | 31.59B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
527.94 | 26.32B | 3.17B | 1.29B | 1.01B | 27.09 |
Evolus Inc Stock (EOLS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-08-06 | 다운그레이드 | Needham | Buy → Hold |
| 2025-04-17 | 개시 | BTIG Research | Buy |
| 2024-01-29 | 업그레이드 | Barclays | Equal Weight → Overweight |
| 2022-06-23 | 개시 | Needham | Buy |
| 2022-05-12 | 업그레이드 | Barclays | Underweight → Equal Weight |
| 2022-01-20 | 업그레이드 | Truist | Hold → Buy |
| 2021-05-06 | 업그레이드 | Mizuho | Neutral → Buy |
| 2021-04-08 | 재확인 | H.C. Wainwright | Buy |
| 2021-02-24 | 다운그레이드 | Truist | Buy → Hold |
| 2020-07-07 | 다운그레이드 | Mizuho | Buy → Neutral |
| 2020-02-06 | 재개 | Mizuho | Buy |
| 2019-11-26 | 개시 | SVB Leerink | Outperform |
| 2019-09-05 | 재개 | Mizuho | Buy |
| 2019-06-28 | 개시 | Wells Fargo | Market Perform |
| 2019-06-11 | 개시 | Barclays | Underweight |
| 2019-03-20 | 개시 | SunTrust | Buy |
| 2019-02-14 | 개시 | H.C. Wainwright | Buy |
| 2019-01-29 | 개시 | Stifel | Buy |
모두보기
Evolus Inc 주식(EOLS)의 최신 뉴스
Evolus Inc (EOLS) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Evolus, Inc. Common Stock Revenue Breakdown – NASDAQ:EOLS - TradingView
Evolus Inc (EOLS) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Evolus, Inc. (EOLS) Q2 2023 Earnings ReportResults, Call & Slides - TipRanks
Evolus Inc (EOLS) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Evolus, Inc. (EOLS) Q2 2025 Earnings ReportResults, Call & Slides - TipRanks
Evolus Inc (EOLS) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Evolus, Inc. (EOLS) Q1 2024 Earnings ReportResults, Call & Slides - TipRanks
Press Release: Evolus to Report Second Quarter Financial Results on August 5, 2026 - Moomoo
Evolus to Report Second Quarter Financial Results on August 5, 2026 - Yahoo Finance
Evolus Inc. (EOLS) Slips 3.2% as Stock Approaches Key Support LevelCall Wall - dars.gov.et
Evolus, Inc. (EVL) Q2 2023 Earnings ReportResults, Call & Slides - TipRanks
Evolus, Inc. (EVL) Q3 2025 Earnings ReportResults, Call & Slides - TipRanks
Evolus, Inc. (EVL) Q2 2025 Earnings ReportResults, Call & Slides - TipRanks
Evolus, Inc. (EVL) Q1 2024 Earnings ReportResults, Call & Slides - TipRanks
Evolus, Inc. (EVL) Q3 2024 Earnings ReportResults, Call & Slides - TipRanks
(EOLS) and the Role of Price-Sensitive Allocations - Stock Traders Daily
Analysts Conflicted on These Healthcare Names: Irhythm Technologies (IRTC), Penumbra (PEN) and Evolus (EOLS) - The Globe and Mail
Evolus signs licensing deal for Profhilo skin injectable in US By Investing.com - Investing.com Nigeria
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
Evolus Class Action Reminder - TMX Newsfile
Analysts’ Top Healthcare Picks: Evolus (EOLS), Annovis Bio (ANVS) - The Globe and Mail
One Formula, One Platform: Inside the Preclinical Milestone Behind Conexeu's Move Into Medical Aesthetics - Finansavisen
ETFs Investing in Evolus, Inc. Stocks - TradingView
Evolus Lands Licensing Rights for Profhilo - Orange County Business Journal
Evolus, IBSA Partner to Develop and Commercialize Skin Quality Filler in the US - The Dermatology Digest
Evolus Partners with IBSA to Launch Profhilo® Injectable for Skin Quality in the U.S., Expanding Aesthetic Portfolio - Minichart
Evolus signs licensing deal for Profhilo skin injectable in US - Investing.com
Evolus Partners With IBSA to Develop, Commercialize Profhilo in US - Moomoo
Evolus Secures Exclusive U.S. Profhilo License From IBSA; No Upfronts, 15-Year Term - TradingView
Evolus Announces Partnership with IBSA to Develop and Commercialize Market-Leading Profhilo® in the United States, Expanding Its Injectable Portfolio into Skin Quality - Yahoo! Finance Canada
Needham Maintains Evolus(EOLS.US) With Hold Rating - Moomoo
Evolus (EOLS) Slides 0.86% as Stock Hovers Near Support – Market Sentiment Weighs on Aesthetics PlayerBeta Neutral Pair - dars.gov.et
EOLSEvolus Inc Options - Finviz
Evolus (EOLS) price target decreased by 11.11% to 14.96 - MSN
Evolus Q1 2026 earnings preview - MSN
Price to sales forward of Evolus, Inc. Common Stock – NASDAQ:EOLS - TradingView
Enterprise value to EBITDA forward of Evolus, Inc. Common Stock – NASDAQ:EOLS - TradingView
Enterprise value to revenue forward of Evolus, Inc. Common Stock – NASDAQ:EOLS - TradingView
Evolus, Inc. Actuals & Estimates (NASDAQ:EOLS) - TradingView
EVL Forecast — Price Target — Prediction for 2027 - TradingView
EOLS Forecast — Price Target — Prediction for 2027 - TradingView
Evolus Inc. (EOLS) Q1 2026 Earnings: EPS Surpasses Estimates, Signaling Operational ImprovementsEarnings Decline Risk - dars.gov.et
EOLS News | EVOLUS INC (NASDAQ:EOLS) - ChartMill
Evolus Inc (EOLS) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Evolus, Inc.(NasdaqGM: EOLS) added to S&P Pharmaceuticals Select Industry Index - marketscreener.com
Is Evolus (EOLS) Finally Turning the Corner on Profitability - Kavout | AI
Evolus Inc. Q1 2026 Earnings: EPS Surprises Sharply to the Upside as Investor Sentiment Stays MutedEarnings Momentum Score - dars.gov.et
EOLS Q1 2026 Earnings: EPS Beat Expectations Despite Narrow LossProfit Recovery Report - DonanımHaber
Evolus Inc (EOLS) Valuation: PE, PB & Fair Value Analysis - TradingKey
Evolus Inc (EOLS) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Evolus Inc (EOLS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.30%
2.01%
자본화:
|
볼륨(24시간):